Canada markets closed

Assure Holdings Corp. (IOM.V)

TSXV - TSXV Real Time Price. Currency in CAD
Add to watchlist
0.9500-0.0500 (-5.00%)
At close: 10:56AM EDT
Full screen
Previous Close1.0000
Open1.0000
Bid0.9700 x 0
Ask1.0000 x 0
Day's Range0.9500 - 1.0000
52 Week Range0.8100 - 2.3400
Volume5,200
Avg. Volume9,503
Market Cap33.223M
Beta (5Y Monthly)1.82
PE Ratio (TTM)N/A
EPS (TTM)-0.4830
Earnings DateAug. 31, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est3.00
  • Assure Holdings Launches Marketing Campaign Directed at Medical Device Distributors
    GlobeNewswire

    Assure Holdings Launches Marketing Campaign Directed at Medical Device Distributors

    DENVER, Oct. 21, 2020 (GLOBE NEWSWIRE) -- Assure Holdings Corp. (the “Company” or “Assure”) (TSXV: IOM; OTCQB: ARHH), a provider of intraoperative neuromonitoring services (“IONM”), has announced the launching of a digital marketing campaign to bolster its channel program recruiting medical device distributor partners (“Distributor Campaign”). This business development initiative is an important element of the Company’s growth acceleration strategy. John A. Farlinger, executive chairman and CEO, said, “Assure already has contracts signed with a number of medical device distributors and it expects this digital campaign to generate additional partnerships.”The Distributor Campaign will be driven by Gary Bennett, Assure’s Vice President of Revenue. The marketing program automates five business growth components across multiple digital channels including: lead generation, prospect nurturing, client engagement, referral generation and workflow automation.About Assure Holdings Assure Holdings Corp. is a Colorado-based company that works with neurosurgeons and orthopedic spine surgeons to provide a turnkey suite of services that support intraoperative neuromonitoring activities during invasive surgeries. Assure employs its own staff of technologists and uses its own state-of-the-art monitoring equipment, handles 100% of intraoperative neuromonitoring scheduling and setup, and bills for all technical services provided. Assure Neuromonitoring is recognized as providing the highest level of patient care in the industry and has earned the Joint Commission’s Gold Seal of Approval®. For more information, visit the company’s website at www.assureneuromonitoring.com.Forward-Looking Statements This news release may contain “forward-looking statements” within the meaning of applicable securities laws, including but not limited to: comments with respect to the Company’s future growth and the Distributor Campaign as an important element of the Company’s growth acceleration strategy; future actions of the Company; the Distributor Campaign and its ability to generate additional partners. Forward-looking statements may generally be identified by the use of the words "anticipates," "expects," "intends," "plans," "should," "could," "would," "may," "will," "believes," "estimates," "potential," "target," or "continue" and variations or similar expressions. These statements are based upon the current expectations and beliefs of management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include, but are not limited to: the Company’s ability to continue to grow; the Distributor Campaign may not result in the acceleration of the Company’s growth; the Distributor Campaign may not generate additional partners; the uncertainty surrounding the spread of COVID-19 and the impact it will have on the Company’s operations and economic activity in general; and the risks and uncertainties discussed in our most recent annual and quarterly reports filed with the Canadian securities regulators and available on the Company’s profile on SEDAR at www.sedar.com, which risks and uncertainties are incorporated herein by reference. Readers are cautioned not to place undue reliance on forward-looking statements. Except as required by law, Assure does not intend, and undertakes no obligation, to update any forward-looking statements to reflect, in particular, new information or future events.Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.Contact Scott Kozak, Investor and Media Relations Assure Holdings Corp. 1-720-287-3093 Scott.Kozak@assureiom.com

  • Assure Holdings Announces the Establishment of a New Technologist Training and Education Program
    GlobeNewswire

    Assure Holdings Announces the Establishment of a New Technologist Training and Education Program

    Ramesh Vijay Named Director of EducationDENVER, Oct. 20, 2020 (GLOBE NEWSWIRE) -- Assure Holdings Corp. (the “Company” or “Assure”) (TSXV: IOM; OTCQB: ARHH), a provider of intraoperative neuromonitoring services (“IONM”), has announced a new education and training program for technologists. To lead this effort, the Company has appointed Ramesh Vijay to the newly created director of education position. “Given the limited number of trained certified IONM technologists, estimated at approximately 5,000 individuals nationwide, building our own talent pipeline is essential to prepare for our anticipated growth and maintaining exceptional service,” said John A. Farlinger, Assure’s executive chairman and CEO. “To alleviate the bottleneck for technologists and foster the pipeline necessary for staffing our growth opportunities, Assure is developing our own technologist training program. We will be one of only a handful of IONM companies that are developing our own talent in this manner.”Vijay will oversee Assure’s training program. This will include educating newly hired non board-certified technologists via didactic courses, clinical training and board preparation as well as the development of continuing education and advanced training for the clinical team. In addition, Vijay will spearhead Assure’s IONM clinical research projects, act as a Company representative for industry organizations including ASET, ASNM and ACNS, provide intermittent technologist case coverage, support business development efforts and serve as a member of the Clinical Leadership Team.Farlinger continued, “Assure’s current and future success is rooted in the care we have taken to hire, develop, and retain the best, most dedicated technologists. The demonstrated expertise Ramesh brings to the organization supports our development plans and aligns with our principles.”Farlinger concluded, “In addition, Ramesh will play an important role on research projects relating to IONM efficacy, safety, cost savings and improving patient outcomes that we are planning to launch through our collaboration with the surgeons at the internationally renowned Texas Back Institute. We envision numerous ways that this research will help Assure and the IONM industry as a whole.”With an emphasis on training, patient care, clinical research and quality assurance, Mr. Vijay previously served as an educational leader and IONM technologist at multiple organizations including Specialty Care. Mr. Vijay has also worked as an instructor and researcher in higher education at Harvard Medical School, as an Assistant Professor in the Department of Pediatrics at the University of Louisville and most recently as an Assistant Professor in the Department of Pediatrics at the University of Chicago.Mr. Vijay earned a Doctorate and Master’s Degree at the Aligarh Muslim University / All India Institute of Medical Sciences and a Master and Bachelor of Science from Bangalore University. He also completed a Postdoctoral Fellowship at the Stanford University School of Medicine.Assure’s education and training program, which launched in the fourth quarter of 2020, will include lectures and classroom work, laboratory practicums, online instruction and operating room clinicals. It will also incorporate university internships and additional educational opportunities past the board certification, all with the goal of preparing these candidates to pass the CNIM certification exam and ultimately join Assure’s workforce. The education program will allow Assure to teach and mold these technologists as they prepare for a career in IONM and help the Company maintain rigorous quality control standards and the clinical excellence that Assure demands for the surgeons it supports and the patients it serves.About Assure Holdings Assure Holdings Corp. is a Colorado-based company that works with neurosurgeons and orthopedic spine surgeons to provide a turnkey suite of services that support intraoperative neuromonitoring activities during invasive surgeries. Assure employs its own staff of technologists and uses its own state-of-the-art monitoring equipment, handles 100% of intraoperative neuromonitoring scheduling and setup, and bills for all technical services provided. Assure Neuromonitoring is recognized as providing the highest level of patient care in the industry and has earned the Joint Commission’s Gold Seal of Approval®. For more information, visit the company’s website at www.assureneuromonitoring.com.Forward-Looking Statements This news release may contain “forward-looking statements” within the meaning of applicable securities laws, including but not limited to: comments with respect to the Company’s future growth; future actions of the Company and the expected effects of certain research projects relating to IONM. Forward-looking statements may generally be identified by the use of the words "anticipates," "expects," "intends," "plans," "should," "could," "would," "may," "will," "believes," "estimates," "potential," "target," or "continue" and variations or similar expressions. These statements are based upon the current expectations and beliefs of management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include, but are not limited to: the Company’s ability to continue to grow; the enrollment for the Company’s training program; the uncertainty surrounding the spread of COVID-19 and the impact it will have on the Company’s operations and economic activity in general; and the risks and uncertainties discussed in our most recent annual and quarterly reports filed with the Canadian securities regulators and available on the Company’s profile on SEDAR at www.sedar.com, which risks and uncertainties are incorporated herein by reference. Readers are cautioned not to place undue reliance on forward-looking statements. Except as required by law, Assure does not intend, and undertakes no obligation, to update any forward-looking statements to reflect, in particular, new information or future events.Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.Contact Scott Kozak, Investor and Media Relations Assure Holdings Corp. 1-720-287-3093 Scott.Kozak@assureiom.com

  • GlobeNewswire

    Assure Reports its Highest Number of Monthly Procedures in 2020 with Strong September Results

    Company’s 2020 Cash Collection Through September Exceeds Full Year 2019 TotalDENVER, Oct. 08, 2020 (GLOBE NEWSWIRE) -- Assure Holdings Corp. (the “Company” or “Assure”) (TSXV: IOM; OTCQB: ARHH), a provider of intraoperative neuromonitoring services, announced its highest number of monthly procedures in 2020 during September. “The Company reported our highest number of monthly procedures so far this year in September, managing more than 900 cases, and extending our resurgence in demand to five months following the sharply negative impact of COVID-19 on elective procedures in March and April,” said John A. Farlinger, Assure’s executive chairman and CEO. ”Although we are continuing to carefully monitor the impact of COVID-19 in all states within our operational footprint, the Company forecasts a record performance over the final three months of the year aided by the seasonal strength we typically experience in the fourth quarter.”Progress in Billing and Collections Farlinger continued, “Since bringing revenue cycle management in-house, our revamped collections process has greatly strengthened and improved the Company’s financial position. We took control of this process from the legacy 3rd party vendor that was terminated in the autumn of 2019 because of poor performance. Assure has substantially improved cash collection in 2020 and we expect results to continue accelerating in 2021.”The Company collected more than US$10.1 million in the first nine months of 2020. This compares to full-year 2019 cash collections of US$8.0 million. These cash receipt figures referenced relate to technologist services and Professional Network Entities (“PNEs”) that the Company owns 100%, but does not include collections from PNEs owned less than 100% by Assure, which are recorded separately.Farlinger added, “As we look to finish the year strong, we are focused on driving a significant portion of our commercial insurance-related revenue into in-network agreements to accelerate payments and reduce volatility. Approximately 20% of the Company’s commercial insurance volume is currently supported by in-network agreements on a run-rate basis, either through direct agreements with the payors or through indirect agreements with aggregators, and we expect this to increase to approximately 30% by end of year 2020, with a goal of reaching approximately 50% by end of year 2021.”About Assure Holdings Assure Holdings Corp. is a Colorado-based company that works with neurosurgeons and orthopedic spine surgeons to provide a turnkey suite of services that support intraoperative neuromonitoring activities during invasive surgeries. Assure employs its own staff of technologists and uses its own state-of-the-art monitoring equipment, handles 100% of intraoperative neuromonitoring scheduling and setup, and bills for all technical services provided. Assure Neuromonitoring is recognized as providing the highest level of patient care in the industry and has earned The Joint Commission’s Gold Seal of Approval®. For more information, visit the company’s website at www.assureneuromonitoring.com.Non-IFRS Measures This press release includes certain measures which have not been prepared in accordance with International Financial Reporting Standards (“IFRS”) such as commercial insurance volume and cases. The non-IFRS measures presented are unlikely to be comparable to similar measures presented by other issuers. References to commercial insurance volume and cases are monitored by the Company. None of the foregoing non-IFRS measures is an earnings measure recognized by IFRS and do not have a standardized meaning prescribed by IFRS. Management believes that commercial insurance volume and cases are appropriate measures in evaluating the Company’s performance. Readers are cautioned that commercial insurance volume and cases should not be construed as alternatives to net income (as determined under IFRS), as indicators of financial performance or to cash flow from operating activities (as determined under IFRS) or as measures of liquidity and cash flow.Forward-Looking Statements This news release may contain “forward-looking statements” within the meaning of applicable securities laws, including, but not limited to: comments with respect to: strategies; expectations; planned operations; the number of procedures monitored by the Company; the Company’s number of monthly procedures performed by the Company; the demand for the Company’s IONM services; the Company’s revamped collections process and its effect on the financial position of the Company; the Company’s commercial insurance revenues generated by its in-network agreements; the Company’s collection of reimbursement from hospitals at it performs cases for patients with public insurance; the Company’s continuing increase in the proportion of its hospital contracts that cover government cases; future actions of the Company and other expected effects of the Company’s practices related to its billing and collections procedures; the success of the revenue cycle management process and the Company’s ability to collect on future and outstanding claims.. Forward-looking statements may generally be identified by the use of the words "anticipates," "expects," "intends," "plans," "should," "could," "would," "may," "will," "believes," "estimates," "potential," "target," or "continue" and variations or similar expressions. These statements are based upon the current expectations and beliefs of management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include, but are not limited to: the uncertainty surrounding the spread of COVID-19 and the impact it will have on the Company’s operations and economic activity in general; that the Company’s actions taken during the COVID-19 health crisis will be effective; the Company’s number of monthly procedures may not continue to rise an achieve record breaking numbers in the final three months of 2020; the demand for the Company’s IONM services will continue increase over the final three months of 2020; the Company’s ability to remain cashflow positive; the Company’s financial position may not continue to improve as a result of its revamped collections process; the Company’s cash collections and billings may not continue to increase in 2021; the Company’s commercial insurance revenues generated by its in-network agreements may not increase to: (i) 30% by the end of 2020 and (ii) 50% by the end of 2021; the Company’s collection of reimbursement from hospitals at it performs cases for patients with public insurance may not continue to improve; the Company may not continue to increase the proportion of hospital contracts that cover government cases ; and the risks and uncertainties discussed in our most recent annual and quarterly reports filed with the Canadian securities regulators and available on the Company’s profile on SEDAR at www.sedar.com, which risks and uncertainties are incorporated herein by reference. Readers are cautioned not to place undue reliance on forward-looking statements. Except as required by law, Assure does not intend, and undertakes no obligation, to update any forward-looking statements to reflect, in particular, new information or future events.Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.Contact Scott Kozak, Investor and Media Relations Assure Holdings Corp. 1-720-287-3093 Scott.Kozak@assureiom.comJohn Farlinger, Chief Executive Officer Assure Holdings Corp. 1-604-763-7565 John.Farlinger@assureiom.com